vs
Side-by-side financial comparison of LXP Industrial Trust (LXP) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $86.7M, roughly 1.4× LXP Industrial Trust). LXP Industrial Trust runs the higher net margin — 33.2% vs 3.3%, a 29.9% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -14.0%). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs 0.3%).
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
LXP vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.7M | $123.8M |
| Net Profit | $28.8M | $4.1M |
| Gross Margin | 81.5% | 72.5% |
| Operating Margin | 34.6% | 4.3% |
| Net Margin | 33.2% | 3.3% |
| Revenue YoY | -14.0% | 4.7% |
| Net Profit YoY | — | 1379.4% |
| EPS (diluted) | — | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.7M | $123.8M | ||
| Q3 25 | $86.9M | $128.3M | ||
| Q2 25 | $87.7M | $114.8M | ||
| Q1 25 | $88.9M | $113.2M | ||
| Q4 24 | $100.9M | $118.2M | ||
| Q3 24 | $85.6M | $114.6M | ||
| Q2 24 | $85.8M | $110.6M | ||
| Q1 24 | $86.3M | $111.0M |
| Q4 25 | $28.8M | $4.1M | ||
| Q3 25 | $36.3M | $5.3M | ||
| Q2 25 | $29.1M | $5.3M | ||
| Q1 25 | $19.0M | $4.7M | ||
| Q4 24 | — | $-321.0K | ||
| Q3 24 | $6.3M | $4.3M | ||
| Q2 24 | $5.4M | $1.3M | ||
| Q1 24 | $-269.0K | $2.3M |
| Q4 25 | 81.5% | 72.5% | ||
| Q3 25 | 82.3% | 73.3% | ||
| Q2 25 | 81.9% | 71.7% | ||
| Q1 25 | 80.7% | 72.1% | ||
| Q4 24 | 85.3% | 72.0% | ||
| Q3 24 | 82.5% | 71.3% | ||
| Q2 24 | 82.0% | 71.4% | ||
| Q1 24 | 82.4% | 71.2% |
| Q4 25 | 34.6% | 4.3% | ||
| Q3 25 | 50.4% | 7.0% | ||
| Q2 25 | 33.7% | 3.7% | ||
| Q1 25 | 21.8% | 5.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | 7.9% | 4.6% | ||
| Q2 24 | 6.9% | 5.1% | ||
| Q1 24 | 1.0% | 4.2% |
| Q4 25 | 33.2% | 3.3% | ||
| Q3 25 | 41.7% | 4.2% | ||
| Q2 25 | 33.2% | 4.6% | ||
| Q1 25 | 21.4% | 4.2% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | 7.4% | 3.8% | ||
| Q2 24 | 6.3% | 1.2% | ||
| Q1 24 | -0.3% | 2.1% |
| Q4 25 | — | $0.23 | ||
| Q3 25 | $0.12 | $0.30 | ||
| Q2 25 | $0.09 | $0.28 | ||
| Q1 25 | $0.06 | $0.25 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $0.02 | $0.23 | ||
| Q2 24 | $0.01 | $0.07 | ||
| Q1 24 | $-0.01 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $170.4M | $93.9M |
| Total DebtLower is stronger | $1.4B | — |
| Stockholders' EquityBook value | $2.0B | $161.6M |
| Total Assets | $3.5B | $261.1M |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.4M | $93.9M | ||
| Q3 25 | $229.7M | $95.6M | ||
| Q2 25 | $71.0M | $81.3M | ||
| Q1 25 | $70.9M | $86.5M | ||
| Q4 24 | $101.8M | $84.7M | ||
| Q3 24 | $55.0M | $78.7M | ||
| Q2 24 | $48.7M | $68.7M | ||
| Q1 24 | $293.8M | $77.8M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $2.0B | $161.6M | ||
| Q3 25 | $2.1B | $166.7M | ||
| Q2 25 | $2.1B | $163.7M | ||
| Q1 25 | $2.1B | $167.1M | ||
| Q4 24 | $2.1B | $161.0M | ||
| Q3 24 | $2.1B | $162.6M | ||
| Q2 24 | $2.1B | $156.4M | ||
| Q1 24 | $2.2B | $159.7M |
| Q4 25 | $3.5B | $261.1M | ||
| Q3 25 | $3.7B | $264.8M | ||
| Q2 25 | $3.7B | $254.9M | ||
| Q1 25 | $3.8B | $252.7M | ||
| Q4 24 | $3.8B | $240.9M | ||
| Q3 24 | $3.9B | $245.3M | ||
| Q2 24 | $3.9B | $235.8M | ||
| Q1 24 | $4.2B | $247.3M |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $188.7M | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 6.56× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $188.7M | $9.9M | ||
| Q3 25 | $63.5M | $18.5M | ||
| Q2 25 | $44.3M | $4.3M | ||
| Q1 25 | $39.0M | $2.6M | ||
| Q4 24 | $211.2M | $12.2M | ||
| Q3 24 | $64.6M | $9.6M | ||
| Q2 24 | $38.5M | $1.3M | ||
| Q1 24 | $38.9M | $2.2M |
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -1.4% |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | 6.56× | 2.41× | ||
| Q3 25 | 1.75× | 3.46× | ||
| Q2 25 | 1.52× | 0.81× | ||
| Q1 25 | 2.05× | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | 2.21× | ||
| Q2 24 | 7.09× | 0.97× | ||
| Q1 24 | — | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LXP
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
